Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/RSF1_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/RSF1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/RSF1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/RSF1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/RSF1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/RSF1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/RSF1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/RSF1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/RSF1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/RSF1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004802531 | Oral cavity | NEOLP | negative regulation of mRNA splicing, via spliceosome | 9/2005 | 20/18723 | 1.02e-04 | 1.23e-03 | 9 |
GO:004544622 | Oral cavity | NEOLP | endothelial cell differentiation | 27/2005 | 118/18723 | 1.03e-04 | 1.24e-03 | 27 |
GO:007005932 | Oral cavity | NEOLP | intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress | 17/2005 | 63/18723 | 2.45e-04 | 2.54e-03 | 17 |
GO:001908031 | Oral cavity | NEOLP | viral gene expression | 22/2005 | 94/18723 | 3.10e-04 | 3.05e-03 | 22 |
GO:00182122 | Oral cavity | NEOLP | peptidyl-tyrosine modification | 62/2005 | 378/18723 | 4.27e-04 | 3.91e-03 | 62 |
GO:004586024 | Oral cavity | NEOLP | positive regulation of protein kinase activity | 63/2005 | 386/18723 | 4.41e-04 | 3.99e-03 | 63 |
GO:005068631 | Oral cavity | NEOLP | negative regulation of mRNA processing | 10/2005 | 29/18723 | 5.71e-04 | 4.96e-03 | 10 |
GO:00181082 | Oral cavity | NEOLP | peptidyl-tyrosine phosphorylation | 61/2005 | 375/18723 | 5.88e-04 | 5.08e-03 | 61 |
GO:007121424 | Oral cavity | NEOLP | cellular response to abiotic stimulus | 55/2005 | 331/18723 | 6.38e-04 | 5.43e-03 | 55 |
GO:010400424 | Oral cavity | NEOLP | cellular response to environmental stimulus | 55/2005 | 331/18723 | 6.38e-04 | 5.43e-03 | 55 |
GO:000863031 | Oral cavity | NEOLP | intrinsic apoptotic signaling pathway in response to DNA damage | 22/2005 | 99/18723 | 6.64e-04 | 5.54e-03 | 22 |
GO:001648231 | Oral cavity | NEOLP | cytosolic transport | 32/2005 | 168/18723 | 8.71e-04 | 6.86e-03 | 32 |
GO:000188524 | Oral cavity | NEOLP | endothelial cell development | 16/2005 | 64/18723 | 9.25e-04 | 7.19e-03 | 16 |
GO:003134922 | Oral cavity | NEOLP | positive regulation of defense response | 47/2005 | 278/18723 | 1.05e-03 | 7.99e-03 | 47 |
GO:000317011 | Oral cavity | NEOLP | heart valve development | 16/2005 | 65/18723 | 1.11e-03 | 8.33e-03 | 16 |
GO:005105113 | Oral cavity | NEOLP | negative regulation of transport | 72/2005 | 470/18723 | 1.14e-03 | 8.49e-03 | 72 |
GO:003134811 | Oral cavity | NEOLP | negative regulation of defense response | 44/2005 | 258/18723 | 1.24e-03 | 9.13e-03 | 44 |
GO:00031761 | Oral cavity | NEOLP | aortic valve development | 11/2005 | 37/18723 | 1.26e-03 | 9.21e-03 | 11 |
GO:001908321 | Oral cavity | NEOLP | viral transcription | 13/2005 | 50/18723 | 1.85e-03 | 1.27e-02 | 13 |
GO:005072712 | Oral cavity | NEOLP | regulation of inflammatory response | 60/2005 | 386/18723 | 1.99e-03 | 1.33e-02 | 60 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RSF1 | SNV | Missense_Mutation | | c.1989A>C | p.Lys663Asn | p.K663N | Q96T23 | protein_coding | tolerated_low_confidence(0.23) | benign(0) | TCGA-A2-A0EV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RSF1 | SNV | Missense_Mutation | novel | c.1274G>C | p.Cys425Ser | p.C425S | Q96T23 | protein_coding | tolerated_low_confidence(0.33) | benign(0.031) | TCGA-A2-A3XT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | PR |
RSF1 | SNV | Missense_Mutation | rs779258393 | c.3217G>A | p.Glu1073Lys | p.E1073K | Q96T23 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-A8-A09E-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
RSF1 | SNV | Missense_Mutation | novel | c.334N>A | p.Leu112Ile | p.L112I | Q96T23 | protein_coding | tolerated(0.06) | benign(0.321) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RSF1 | SNV | Missense_Mutation | novel | c.3529G>C | p.Glu1177Gln | p.E1177Q | Q96T23 | protein_coding | deleterious(0.02) | possibly_damaging(0.725) | TCGA-AN-A0FL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RSF1 | SNV | Missense_Mutation | | c.2074G>C | p.Glu692Gln | p.E692Q | Q96T23 | protein_coding | deleterious(0.03) | benign(0.203) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
RSF1 | SNV | Missense_Mutation | | c.1645N>T | p.Asp549Tyr | p.D549Y | Q96T23 | protein_coding | deleterious_low_confidence(0) | benign(0.406) | TCGA-BH-A0DG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
RSF1 | SNV | Missense_Mutation | | c.2905N>C | p.Glu969Gln | p.E969Q | Q96T23 | protein_coding | deleterious(0.04) | possibly_damaging(0.734) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RSF1 | SNV | Missense_Mutation | novel | c.3947N>C | p.Gly1316Ala | p.G1316A | Q96T23 | protein_coding | tolerated_low_confidence(0.19) | benign(0.15) | TCGA-LL-A5YL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
RSF1 | insertion | In_Frame_Ins | novel | c.1529_1530insCCT | p.Arg510delinsSerLeu | p.R510delinsSL | Q96T23 | protein_coding | | | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | | SD |